During the COVID-19 pandemic, new technologies have enabled the biopharmaceutical industry to develop therapeutic antibodies fast.

Andrew Bradbury PhD, Chief Scientific Officer of Specifica, will discuss their next-generation antibody library platform that provides robust antibody diversity and delivers superior therapeutics. Andrew discusses how Carterra’s high throughput kinetics and epitope binning technologies enable the rapid discovery of SARS-CoV-2 neutralizing antibodies.

Noah T. Ditto, Technical Product Manager at Carterra will discuss how high throughput Surface Plasmon Resonance (HT-SPR) facilitates a paradigm shift in antibody screening and characterization—now discover therapeutic candidates in days vs. months.

Posted by Noah T. Ditto